Phathom Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-…

Biotechnology
US, Florham Park [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Phathom Pharmaceuticals, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Phathom Pharmaceuticals, Inc. can't present revenue by segment

Get PRO Today

With PRO you can bypass the blur for the segment revenues of Phathom Pharmaceuticals, Inc..

If you want to see a demo, head over to the financial segments of AAPL

End of PHAT's Analysis
CIK: 1783183 CUSIP: 71722W107 ISIN: US71722W1071 LEI: - UEI: -
Secondary Listings
PHAT has no secondary listings inside our databases.